左卡尼汀治疗慢性心力衰竭所致心肾综合征临床效果研究

[目的]研究左卡尼汀对慢性心功能不全所致心肾综合征患者的心、肾功能的影响,为指导临床治疗提供理论依据.[方法]选择2007-2009年我院接诊的慢性心力衰竭合并肾功能损害患者63例,随机分为实验组31例和对照组32例,基础治疗相同,实验组联合应用左卡尼汀3g/d,静脉滴注,疗程14d,治疗后观察两组患者各项心肾功能指标变化情况,应用SPSS 17.0统计学软件进行数据分析.[结果]两组患者治疗后心肾功能评价指标明显改善.联合左卡尼汀治疗组血红蛋白、CysC及BNP浓度较对照组改善更为明显(P＜0.05),LVEDD明显缩小(P＜0.05),LVEF显著提高(P＜0.05),两组血糖、血脂及血肌酐降低程度无统计学差异(P＞0.05).[结论]基础治疗联合左卡尼汀静脉滴注可进一步改善慢性心肾综合征患者的心肾功能指标.

Clinical efficacy of L-carnitine in treating cardiorenal syndrome results from chronic heart failure

【Objective】To investigate the effects of L-carnitine on cardiac and renal function in treating cardiorenal syndrome results from chronic heart failure,so as to provide additional theoretical basis for clinical treatment.【Methods】A total of 63 patients with chronic heart failure complicating kidney dysfunction were recruited from 2007 to 2009.These patients were randomly divided into vehicle treated group and L-carnitine treated group.All patients were treated with optimal pharmacotherapy according to guideline recommendations.Besides these,L-carnitine group were treated with intravenous drip of L-carnitine.The dosage was 3 g/d and the course of treatment was 14 days.Changes of cardiac and renal function of these two groups at the end were analyzed.SPSS 17.0 was used for data analysis.【Results】After treatment,there was marked amelioration of cardiac and renal function in both groups.Compared with the vehicle treated group,blood levels of hemoglobin increased in the L-carnitine group（P 0.05） especiallyin CysC and BNP both decreased（P 0.05）.The left ventricular end diastolic diameter（LVEDD） decreased and left ventricular ejection fraction（LVEF） elevated（P 0.05）.There was no significant difference in serum glucose,total cholesterol and creatinine in the two groups（P 0.05）.【Conclusion】Intravenous drip of L-carnitine combined with basic pharmacotherapy treatment towards chronic cardiorenal syndrome could improve the cardiac and renal function than basic treatment.